Phase II Clinical Trial: Efficacy and Safety of Kaempferia Parviflora in Treatment of Chronic Vertigo Patients

Phase 2

• Conditions: Dizziness; Kaempferia parviflora, chronic vertigo, Dizziness Handicap Inventory, Vestibular function

• Registration Number: TCTR20181122001
• Lead Sponsor: Agricultural Research Development Agency (Public Organization)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-11-22
• Study Completion: 2019-10-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

1. Chronic dizziness patient with symptom persists more than 3 months
2. age between 18-65 years old
3. Consent to participate in the study and able to follow up until finish
4. Never been treated with Kaempferia parviflora or Betahistine in 72 hours prior recruited in to the study
5. Able to read and write in Thai

Exclusion Criteria

1. Patient with diagnosis of BPPV, Vestibular Migraine, Motion Sickness, Height vertigo, Orthostatic Hypotension, Mental or psychiatric problem, Brain or Vestibular nerve tumor
2. Abnormal proprioception test, tremor, hemiplegia paraplegia
3. Patient with asymmetrical SNHL or poor SDS or suspected Acoustic Neuroma
4 Patient with cardiac arrythmia or arrythmia symptoms
5. Patient with active middle ear disease or TM perforate
6. patient who received neuro compressive drugs, aspirin, diuretics,aminoglycosides, anti-cancer,anti-epilepsy, antidepressants
7. Patient with banormal LFT, GFR less than 60
8. Patient who cannot sit and stand
9. Patient who unable to follow up

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement of vertigo symptoms at D60 Score of Dizziness Handicap Inventory †Thai version

Secondary Outcome Measures

Name	Time	Method
Improvement of Vestibular function D30 and D60 Videonystagmography, Caloric test and Posturography